(NASDAQ: ARGX) Argenx Se's forecast annual revenue growth rate of 370.68% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.68%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.18%.
Argenx Se's revenue in 2024 is $39,017,391.On average, 12 Wall Street analysts forecast ARGX's revenue for 2024 to be $128,065,378,903, with the lowest ARGX revenue forecast at $122,349,752,148, and the highest ARGX revenue forecast at $132,562,357,614. On average, 12 Wall Street analysts forecast ARGX's revenue for 2025 to be $185,773,865,031, with the lowest ARGX revenue forecast at $160,988,309,872, and the highest ARGX revenue forecast at $211,229,736,410.
In 2026, ARGX is forecast to generate $243,237,007,051 in revenue, with the lowest revenue forecast at $197,257,141,298 and the highest revenue forecast at $273,416,066,442.